Skip to main content
Premium Trial:

Request an Annual Quote

ArcherDx, HeliTec Partner on Cancer Dx Development

NEW YORK (GenomeWeb) – ArcherDx has partnered with HeliTec on the development of next-generation sequencing-based cancer diagnostics for the Chinese market, the companies announced today.

Under the terms of the deal, the companies will codevelop and cross-license certain NGS technologies with the goal of registering oncology diagnostic kits with the China Food and Drug Administration. In addition, all of ArcherDx's NGS assays — including its FusionPlex RNA assays, VariantPlex DNA assays, Reveal ctDNA 28 kit, and Immunoverse T-cell receptor kit — are now available from Shenzhen-based HeliTec.

The companies noted that HeliTec is also currently evaluating the Reveal assay to identify oncogenic mutations in liquid biopsies in a recently announced large-scale clinical study.

Additional terms of the deal were not disclosed.

"We are pleased to work with Archer to co-develop cutting-edge, NGS-based diagnostic assays in China, particularly on those cancer types predominant in Asian populations," HeliTec CEO Dongbin Zhou said in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.